Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.3K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

182
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
182
Ligand Binding Sites02:40

Ligand Binding Sites

14.3K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.3K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of in vitro profiling data of cosmetic ingredients within the Tox21 10K compound library for bioactivity and potential toxicity.

BMC pharmacology & toxicology·2026
Same author

Leveraging machine learning for selective cannabinoid ligand discovery: methods, challenges, and opportunities.

Expert opinion on drug discovery·2026
Same author

Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling.

Frontiers in pharmacology·2026
Same author

Impact of Chemical Quality on High-Throughput in Vitro Assays: A Tox21 Study.

Chemical research in toxicology·2026
Same author

Identification of potential autophagy inducers through high-throughput and high-content imaging analysis.

Molecular pharmacology·2026
Same author

Integrating qHTS and QSAR Models to Identify Safe GPCR-Targeted Compounds: A Focus on hERG-Dependent Cardiotoxicity.

Journal of chemical information and modeling·2026

Related Experiment Video

Updated: Oct 30, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

794

AI-based language models powering drug discovery and development.

Zhichao Liu1, Ruth A Roberts2, Madhu Lal-Nag3

  • 1National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.

Drug Discovery Today
|July 3, 2021
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) language models (LMs) can accelerate drug discovery and development. These AI tools show promise in areas like target identification and clinical trial design, potentially improving treatment innovation.

Keywords:
Artificial intelligenceCOVID-19Drug developmentDrug discoveryLanguage modelsNatural language processing

More Related Videos

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

797
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.9K

Related Experiment Videos

Last Updated: Oct 30, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

794
Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

797
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.9K

Area of Science:

  • Pharmacology
  • Computational Biology
  • Artificial Intelligence

Background:

  • Drug discovery and development is a lengthy, costly, and inefficient process with high failure rates.
  • Artificial intelligence (AI), particularly language models (LMs), is revolutionizing natural language processing (NLP).

Purpose of the Study:

  • To summarize advances in AI-powered LMs for drug discovery and development.
  • To highlight the potential applications of AI-powered LMs across the pharmaceutical pipeline.
  • To discuss the role of AI-powered LMs in developing treatments for Coronavirus 2019 (COVID-19) and other pandemic-potential infectious diseases.

Main Methods:

  • Review of current AI-powered language model advancements.
  • Analysis of AI-LM applications in key areas of drug development.
  • Case study focus on AI-LM strategies for COVID-19 treatment development.

Main Results:

  • AI-powered LMs offer significant potential to enhance efficiency and success rates in drug discovery.
  • Key application areas include target identification, clinical trial design, regulatory decision-making, and pharmacovigilance.
  • AI-LMs are particularly promising for accelerating the development of treatments for infectious diseases like COVID-19, including drug repurposing.

Conclusions:

  • AI-powered LMs represent a transformative technology for pharmaceutical research and development.
  • Addressing current challenges is crucial for fully realizing the potential of AI in medicine.
  • Further research and implementation of AI-LMs can lead to faster and more effective therapeutic solutions.